Alphabet-spun-out AI drug discovery company applying AlphaFold and the Drug Design Engine to therapeutic design
Biotech📍 London, UKFounded 2021
Current Valuation
$12B
as of 2026-Q2
DECACORN
IPO Outlookprivate
Is Isomorphic Labs going public?
No. Isomorphic Labs has no imminent IPO plans on record. It is still private.
What is Isomorphic Labs' valuation in 2026?
Isomorphic Labs is valued at $12B as of 2026-Q2, set by its Series B ($2.1B, May 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Isomorphic Labs is an Alphabet-owned AI drug discovery company spun out of DeepMind in 2021, led by DeepMind founder and CEO Demis Hassabis. Builds on AlphaFold (the protein-structure prediction system that won Hassabis the 2024 Nobel Prize in Chemistry) and the 2026 Drug Design Engine, which extends AlphaFold 3 to predict small-molecule binding affinities and discover new binding pockets directly from amino-acid sequences. Has $3B+ in pharma collaboration deals with Novartis and Eli Lilly (signed January 2024). Raised $600M in March 2025 (its first external round) led by Thrive Capital, followed by a $2.1B follow-on in May 2026 led by Thrive with participation from new investors MGX, Temasek, and CapitalG. Headquartered in London with a second office in Lausanne, Switzerland.
Company Profile
CEO
Demis Hassabis
Founded
2021
HQ
London, UK
Employees
~250
Total Raised
$2.7B
Growth
Pre-revenue (drug pipeline still preclinical)
Last Round
Series B — $2.1B (May 2026) · Lead: Thrive Capital
IPO Status
no imminent plans
Fundraising Status
Series B · $2.1B · 3 mo ago
no imminent plansTotal raised $2.7B
Secondary Market
Implied price / share
$61.5
Open interest
46
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$2.1B
May 2026
Thrive Capital
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Isomorphic Labs — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-08-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
35% of roles posted in last 30d
Open roles
23
via greenhouse
Product-build share
74%
engineering, research, product, design
Trajectory
steady
heavy product build — 74% of open roles are product-building functions (engineering/research/product) — 8 of 23 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Data Scientist (Drug Discovery), LondonHead of Medicinal Chemistry, Drug Design, LondonIntegration Engineer (Third Party Systems), LondonMedical Director, Clinical Development (Oncology), Cambridge, MAML Research Engineer, LondonResearch Leader / Senior Scientist (In vitro / Cellular Pharmacology), Cambridge
Counted from Isomorphic Labs's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.